13 results for "Bai-Rong Xia"

Circulating tumor cells in precision oncology: clinical applications in liquid biopsy and 3D organoid model

Chang Yang; Bai-Rong Xia; Wei-Lin Jin et al.

Cancer Cell International, Vol. 19 No. 1 · 2019 · English · DOAJ Scopus

Abstract Circulating tumor cells (CTCs) are a rare subset of cells found in the blood of patients with solid tumors, which function as a seed for metastases. Cancer cells metastasize through the bloodstream either as single migratory CTCs or as multicellular groupings—CTC clusters. The CTCs…

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

Chang Qing Yang; Bai-Rong Xia; Zhao-Cong Zhang et al.

Frontiers in Immunology · 2020 · English · OpenAlex Scopus

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are the primary treatments for ovarian cancer; however, patients often succumb to recurrence with chemotherapeutic resistance within several years after the initial treatment. In the past two decades, immunotherapy…

Also available at: DOAJ

Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy

Xiao-Yu Li; Ya-Nan Pi; Yao Chen et al.

Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

Cancer cells typically exhibit a tightly regulated program of metabolic plasticity and epigenetic remodeling to meet the demand of uncontrolled cell proliferation. The metabolic–epigenetic axis has recently become an increasingly hot topic in carcinogenesis and offers new avenues for innovative and…

Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential

Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia et al.

Frontiers in Immunology, Vol. 12 · 2021 · English · DOAJ Scopus

Cancer immunotherapy (CIT) is considered a revolutionary advance in the fight against cancer. The complexity of the immune microenvironment determines the success or failure of CIT. Long non-coding RNA (lncRNA) is an extremely versatile molecule that can interact with RNA, DNA, or proteins to…

Corrigendum: Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential

Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia et al.

Frontiers in Immunology, Vol. 13 · 2022 · English · DOAJ Scopus

E2F1/2/7/8 as independent indicators of survival in patients with cervical squamous cell carcinoma

Chang Yang; Zhao-Cong Zhang; Tian -Bo Liu et al.

Cancer Cell International, Vol. 20 No. 1 · 2020 · English · DOAJ Scopus

Abstract Background Cervical cancer is the second leading cause of death in women 20–39 years old. Because coverage for cervical cancer screening is low, and the vaccination rate of human papillomavirus (HPV) is poor in some countries, potential markers to detect the disease at early stages are…

Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms

Ming-Zhu Jin; Bai-Rong Xia; Yu Xu et al.

Frontiers in Oncology, Vol. 8 · 2018 · English · DOAJ Scopus

Chemotherapy with or without radiation remains the first choice for most cancers. However, intolerant side effects and conventional drug resistance restrict actual clinical efficacy. Curaxin CBL0137 is designed to regulate p53 and nuclear factor-κB simultaneously and to prevent the resistance…

Long Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers

Shi-Jia Jin; Ming-Zhu Jin; Bai-Rong Xia et al.

Frontiers in Oncology, Vol. 9 · 2019 · English · DOAJ Scopus

Long noncoding RNAs (lncRNAs) are emerging as important regulators of numerous biological processes, especially in cancer development. Aberrantly expressed and specifically located in tumor cells, they exert distinct functions in different cancers via regulating multiple downstream targets such as…

The PAPSS1 gene is a modulator of response to cisplatin by regulating estrogen receptor alpha signaling activity in ovarian cancer cells

Lei Sun; Wei-Xue Ji; Yan Li et al.

Journal of Ovarian Research, Vol. 16 No. 1 · 2023 · English · DOAJ Scopus

Abstract Background Cancer cells may develop resistance to cisplatin by various mechanisms. Yet, the exact mechanism of cisplatin in ovarian cancer remains unclear. Recent studies have shown that 3’-phospoadenosine 5’-phosphosulfate synthase 1 (PAPSS1) inhibition combined with low-dose cisplatin…

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer

Xu Huang; Xiao-Yu Li; Wu-Lin Shan et al.

Frontiers in Pharmacology, Vol. 14 · 2023 · English · DOAJ Scopus

Currently, for ovarian cancer, which has the highest mortality rate among all gynecological cancers, the standard treatment protocol is initial tumor cytoreductive surgery followed by platinum-based combination chemotherapy. Although the survival rate after standard treatment has improved, the…

Development and Validation of a Prognostic Signature Based on Immune Genes in Cervical Cancer

Yu Chen; Hao Lin; Ya-Nan Pi et al.

Frontiers in Oncology, Vol. 11 · 2021 · English · DOAJ Scopus

BackgroundCervical cancer is one of the most common types of gynecological malignancies worldwide. This study aims to develop an immune signature to predict survival in cervical cancer.MethodThe gene expression data of 296 patients with cervical cancer from The Cancer Genome Atlas database (TCGA)…

Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential

Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng et al.

Frontiers in Cell and Developmental Biology, Vol. 9 · 2021 · English · DOAJ Scopus

Cancer stem cells (CSCs) are sparks for igniting tumor recurrence and the instigators of low response to immunotherapy and drug resistance. As one of the important components of tumor microenvironment, the tumor associated immune microenvironment (TAIM) is driving force for the heterogeneity…